arrow
L

Lorenza Mittempergher

agendia
H指数:19
被引数:1,759

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune subtyping identifies a subset of HR+HER2-early-stage breast cancer patients with a very high likelihood of response to neoadjuvant immunotherapy (IO): Results from 5 IO arms of the I-SPY2 TRIAL
2024-03-220
PRE
Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response to neoadjuvant immunotherapy (IO): results from 5 IO arms of the I-SPY2 TRIAL
2024-03-010
PRE
B-cells and regulatory T-cells in the microenvironment of HER2+breast cancer are associated with decreased survival: a real-world analysis of women with HER2+metastatic breast cancer

HER2乳腺癌微环境中的b细胞和调节性T细胞与生存率降低相关: 对HER2转移性乳腺癌女性的真实世界分析

2023-10-043
OAAI
ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database
2023-03-011
PRE
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant

PIK3CA突变的等位基因表达失衡在乳腺癌中很常见,并且具有预后意义

2022-06-083
OA
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

原发性结直肠肿瘤分子亚型与同期肝转移的一致性研究

2020-04-2416
OAAI
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology
2019-09-0119
OAAI
Comparison of breast cancer molecular subtyping by Immunohistochemistry and by BluePrint® next generation RNA sequencing-based test at University Hospitals Leuven and Curie Institute Paris
2019-02-150
PRE